NCT06309953
A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
Bausch & Lomb Incorporated·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Dry Eye
- Drug/Device/Intervention
- Miebo
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Bausch & Lomb Incorporated
- Location
- Petaluma,Pittsburg,Stillwater,Kansas City,Brecksville, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Feb 28, 2024
- End date
- Jun 28, 2024
- Enrollment
- 100 participants
Primary outcome
Mean change from baseline (CFB) in dry eye symptom severity at Visit 3
Summary
An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in
 Subjects With Dry Eye Disease
ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06309953
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06309953 through Pure Global AI's free database. This Phase 4 trial is sponsored by Bausch & Lomb Incorporated and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.